Fw: ClinicalTrials.gov - Linking Patients to Medical Research Browse Scleroderma,

[Guest guest]

----- Original Message ----- From: Kathi

Sent: Monday, December 30, 2002 9:05 AM

Subject: ClinicalTrials.gov - Linking Patients to Medical Research Browse Scleroderma,

The way I see it, we didn't have "informed consent" when we got these mini toxic site dumps on our chest, we sure as heck Deserve it Now!!! Love, Jewell PLEASE READ THROUGH BOTTOM Keep in mind that many clinical trials can be done through your own doctor's participation and if they require travel, all expenses are usually paid. We can't get the studies we need but we can get in through backdoors like this. Browse : By Condition : Alphabetically : S : Scleroderma, Systemic -------------------------------------------------------------------------------- 9 studies were found. 1. Recruiting Autologous Stem Cell Transplant For Systemic Sclerosis Condition: Scleroderma, Systemic 2. Recruiting Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refract... Conditions: Systemic Sclerosis; Systemic Lupus Erythematosus; Dermatomyositis; Juvenile Rheumatoid Arthritis; Autoimmune Diseases 3. Recruiting Psychological Treatments for Scleroderma Conditions: Pain; Depression; Scleroderma; Systemic Sclerosis 4. Recruiting Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis Condition: Systemic Sclerosis 5. Recruiting Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients with Systemic Sclerosis Condition: Systemic Sclerosis 6. Recruiting Scleroderma Lung Study Conditions: Lung Diseases; Pulmonary Fibrosis; Systemic Scleroderma; Scleroderma, Systemic 7. Recruiting Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients with Early Stage Diffuse Systemic Sclerosis Conditions: Systemic Sclerosis; Scleroderma 8. Recruiting Six month clinical research study for patients with moderate or severe dry eye syndrome Conditions: Keratoconjunctivitis Sicca; Sjogren's Syndrome; Lupus Erythematosus, Systemic; Arthritis, Rheumatoid; Scleroderma, Systemic 9. Recruiting Oral Type I Collagen in Scleroderma Condition: Scleroderma http://clinicaltrials.gov/ct/gui/action/FindCondition?ui=D012595 & recruiting=true Search results for antiphospholipid [ALL-FIELDS] are shown below. -------------------------------------------------------------------------------- 2 studies were found. 1. Recruiting Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome Conditions: Systemic Lupus Erythematosus; Antiphospholipid Antibody Syndrome 2. Recruiting Study of Abnormal Blood Clotting in Children with Stroke Conditions: Abnormalities; Blood Coagulation Disorder; Brain Disease; Cerebrovascular Accident; Vascular Disease http://clinicaltrials.gov/ct/gui/action/SearchAction;jsessionid=CA1D3A8E717C3ECA5E9F85F62EF90907?term=+antiphospholipid+ & submit=Search Search results for lupus [ALL-FIELDS] are shown below. -------------------------------------------------------------------------------- 23 studies were found. 1. Recruiting Study of Systemic Lupus Erythematosus Conditions: Lupus Nephritis; Systemic Lupus Erythematosus 2. Recruiting Monoclonal Antibody Treatment for Systemic Lupus Erythematosus Condition: Systemic Lupus Erythematosus 3. Recruiting Role of Antibodies in Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus Condition: Systemic Lupus Erythematosus 4. Recruiting Humanized LL2IGG to Treat Systemic Lupus Erythematosus Condition: Systemic Lupus Erythematosus 5. Recruiting Dexamethasone in Lupus Congenital Heart Block of Newborns Conditions: Congenital heart block; Neonatal lupus; Atrioventricular nodal dysfunction; Myocardial injury 6. Recruiting Anti-CD20 in Systemic Lupus Erythematosus Condition: Lupus Erythematosus, Systemic 7. Recruiting Study of GL701 in Men with Systemic Lupus Erythematosus Condition: Systemic Lupus Erythematosus 8. Recruiting Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture Condition: Systemic Lupus Erythematosus 9. Recruiting Phase II Study of Ultraviolet A-1 Light Therapy for Systemic Lupus Erythematosus Condition: Systemic Lupus Erythematosus 10. Recruiting Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus Condition: Systemic Lupus Erythematosus 11. Recruiting Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome Conditions: Systemic Lupus Erythematosus; Antiphospholipid Antibody Syndrome 12. Recruiting Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus Condition: Systemic Lupus Erythematosus 13. Recruiting Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus Condition: Lupus Erythematosus, Systemic 14. Recruiting Immune System Related Kidney Disease Conditions: Glomerulonephritis; Lupus Nephritis; Membranous Glomerulonephritis; Nephritis; Nephrotic Syndrome 15. Recruiting High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide Condition: Lupus Erythematosus, Systemic 16. Recruiting Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy 17. Recruiting Six month clinical research study for patients with moderate or severe dry eye syndrome Conditions: Keratoconjunctivitis Sicca; Sjogren's Syndrome; Lupus Erythematosus, Systemic; Arthritis, Rheumatoid; Scleroderma, Systemic 18. Recruiting Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Conditions: Purpura, Schoenlein-Henoch; Graft Versus Host Disease; Anemia, Hemolytic, Autoimmune; Rheumatoid Arthritis; Churg-Strauss Syndrome; ... 19. Recruiting Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refract... Conditions: Systemic Sclerosis; Systemic Lupus Erythematosus; Dermatomyositis; Juvenile Rheumatoid Arthritis; Autoimmune Diseases 20. Recruiting Safety and efficacy of Pletal(cilostazol) for the treatment of juvenile primary and secondary Raynaud’s phenomenon Condition: Secondary Raynaud's 21. Recruiting Blood Component Collection from Patients with Rheumatic Disease and Healthy Volunteers Conditions: Rheumatic Diseases; Healthy 22. Recruiting Genetic Analysis of Immune Disorders Conditions: Healthy; Immunologic Deficiency Syndrome; Job's Syndrome; Severe Combined Immunodeficiency 23. Recruiting Nitric Oxide Therapy for Patients with Sickle Cell Anemia and Secondary Pulmonary HypertensionConditions: Sickle Cell Anemia; Pulmonary Hypertension http://clinicaltrials.gov/ct/gui/action/SearchAction;jsessionid=CA1D3A8E717C3ECA5E9F85F62EF90907?term=lupus Search results for MULTIPLE MYELOMA (MGUS) [ALL-FIELDS] are shown below. -------------------------------------------------------------------------------- 103 studies were found. Here are studies 1 to 50. 1. Recruiting Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma Condition: Multiple Myeloma 2. Recruiting Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma 3. Recruiting Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma 4. Recruiting Combination Chemotherapy in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma 5. Recruiting Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 6. Recruiting Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma Conditions: stage III multiple myeloma; stage I multiple myeloma; stage II multiple myeloma 7. Recruiting Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 8. Recruiting Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy Conditions: stage I multiple myeloma; stage II multiple myeloma; infection; stage III multiple myeloma 9. Recruiting Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma 10. Recruiting Chemotherapy, Vaccine Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma 11. Recruiting Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon alfa in Treating Patients With Advanced Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 12. Recruiting Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma 13. Recruiting Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma 14. Recruiting Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 15. Recruiting Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon alfa in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma 16. Recruiting Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma 17. Recruiting Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma 18. Recruiting O6-benzylguanine Plus Carmustine in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 19. Recruiting Bone Marrow Transplantation in Treating Patients With Multiple Myeloma or Chronic Phase Chronic Myelogenous Leukemia Conditions: stage I multiple myeloma; stage II multiple myeloma; Philadelphia chromosome positive chronic myelogenous leukemia; ... 20. Recruiting Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma 21. Recruiting Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 22. Recruiting Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; infection; refractory plasma cell neoplasm 23. Recruiting Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 24. Recruiting Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: graft versus host disease; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 25. Recruiting Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 26. Recruiting Antineoplaston Therapy in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 27. Recruiting Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis; refractory plasma cell neoplasm 28. Recruiting Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis; refractory plasma cell neoplasm 29. Recruiting Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm 30. Recruiting A Randomized, Open-Label Study of PS-341(VELCADE™) Versus High-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Condition: Multiple Myeloma 31. Recruiting Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Conditions: lymphoma; multiple myeloma 32. Recruiting Epoetin alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Conditions: lymphoma; leukemia; multiple myeloma 33. Recruiting A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients with Multiple Myeloma Condition: Multiple Myeloma 34. Recruiting Treatment with Zometa in patients with breast cancer, multiple myeloma, and prostate cancer with cancer related bone lesions Conditions: Breast Cancer; Multiple Myeloma; Prostate Cancer 35. Recruiting Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma Conditions: prevention of multiple myeloma; multiple myeloma 36. Recruiting High-Dose Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Amyloidosis Conditions: stage I multiple myeloma; stage II multiple myeloma; primary systemic amyloidosis; stage III multiple myeloma; refractory plasma cell neoplasm 37. Recruiting Efficacy Study of 6474 to treat Multiple Myeloma Cancer Condition: Multiple Myeloma 38. Recruiting T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant Condition: Multiple Myeloma 39. Recruiting CDC-501 therapy in relapsed or refractory multiple myeloma Condition: Multiple Myeloma 40. Recruiting Study of the Safety and Efficacy of an Investigational Drug in Adult Patients with Multiple Myeloma Condition: Multiple Myeloma 41. Recruiting Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Conditions: leukemia; lymphoma; multiple myeloma 42. Recruiting PS-341 in Treating Patients With Refractory or Progressive Multiple Myeloma Condition: refractory plasma cell neoplasm 43. Recruiting Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation Condition: refractory plasma cell neoplasm 44. Recruiting Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma Condition: refractory plasma cell neoplasm 45. Not yet recruiting Thalidomide, Dexamethasone, and Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma Condition: refractory plasma cell neoplasm 46. Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Conditions: Hematologic Disease; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorder 47. Recruiting Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Conditions: leukemia; testicular cancer; ovarian epithelial cancer; lymphoma; breast cancer; multiple myeloma; eye cancer; kidney tumor 48. Recruiting Radiation Therapy and Fludarabine Followed by Donor Peripheral Stem Cell Transplantation, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Hematologic Cancer Conditions: leukemia; lymphoma; multiple myeloma 49. Recruiting Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Conditions: leukemia; lymphoma; multiple myeloma 50. Recruiting Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy Conditions: leukemia; testicular cancer; ovarian epithelial cancer; lymphoma; breast cancer; multiple myeloma; kidney tumor 51. Recruiting Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation Conditions: leukemia; testicular cancer; ovarian epithelial cancer; lymphoma; breast cancer; multiple myeloma; kidney tumor 52. Recruiting Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Conditions: leukemia; lymphoma; multiple myeloma 53. Recruiting Donor Bone Marrow Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Conditions: leukemia; multiple myeloma 54. Recruiting Combination Chemotherapy Followed by Donor Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Genetic Disorders Conditions: leukemia; lymphoma; multiple myeloma; eye cancer 55. Recruiting Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation Conditions: leukemia; lymphoma; multiple myeloma 56. Recruiting Alemtuzumab, Total-Body Irradiation, and Fludarabine Followed By Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Conditions: leukemia; lymphoma; multiple myeloma 57. Recruiting Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation Conditions: lymphoma; multiple myeloma 58. Recruiting Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer Conditions: leukemia; testicular cancer; ovarian epithelial cancer; lymphoma; breast cancer; multiple myeloma 59. Recruiting Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Conditions: leukemia; lymphoma; multiple myeloma; eye cancer 60. Recruiting Bone Marrow or Peripheral Stem Cell Transplantation Plus Cyclophosphamide and Radiation Therapy in Treating Patients With Hematologic Cancer Conditions: lymphoma; leukemia; multiple myeloma 61. Recruiting Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Conditions: leukemia; lymphoma; multiple myeloma 62. Recruiting Bone Marrow Transplantation in Treating Patients With Hematologic Cancers Conditions: leukemia; multiple myeloma 63. Recruiting Combination Chemotherapy Plus Alemtuzumab Followed by Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Conditions: leukemia; lymphoma; multiple myeloma 64. Recruiting Combining Chemotherapy, Tacrolimus, Mycophenolate Mofetil, and Radiation Therapy with Donor Bone Marrow Transplantation in Treating Patients with Hematologic Cancer Conditions: leukemia; lymphoma; multiple myeloma 65. Recruiting R115777 in Treating Patients With Advanced Hematologic Cancer Conditions: leukemia; lymphoma; multiple myeloma 66. Recruiting Pyroxamide in Treating Patients With Advanced Cancer Conditions: leukemia; lymphoma; multiple myeloma; eye cancer 67. Recruiting Treatment for Chronic Pain in Patients With Advanced Cancer Conditions: leukemia; lymphoma; multiple myeloma 68. Recruiting 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors Conditions: stage III multiple myeloma; unspecified adult solid tumor, protocol specific; refractory plasma cell neoplasm 69. Recruiting Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Conditions: lung cancer; lip and oral cavity cancer; leukemia; renal cell cancer; head and neck cancer; ovarian sarcoma; ovarian epithelial cancer; lymphoma; ... 70. Recruiting PS-341 in Treating Patients With Advanced Cancer Conditions: leukemia; lymphoma; multiple myeloma 71. Recruiting Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Conditions: leukemia; lymphoma; multiple myeloma 72. Recruiting Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants Conditions: Chronic Lymphocytic Leukemia; Graft vs Host Disease; Hodgkin's Disease; Multiple Myeloma; Non Hodgkin's Lymphoma 73. Recruiting Chemotherapy Related Anemia Conditions: Lymphoma; Leukemia, Lymphocytic, Chronic; Multiple Myeloma; Breast Neoplasms; Lung Neoplasms 74. Recruiting Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies Conditions: Lymphomas; Breast Neoplasms; Lung Neoplasms; Multiple Myeloma; Leukemia, Lymphocytic, Chronic 75. Recruiting CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation Conditions: Chronic Myelogenous Leukemia; Multiple Myeloma; Non Hodgkin's Lymphoma; Hodgkin's Disease; Chronic Lymphocytic Leukemia 76. Not yet recruiting Blood and Marrow Transplant Clinical Research Network Conditions: Bone Marrow Transplantation; Blood Disease; Hematopoietic Stem Cell Transplantation; Leukemia; Multiple Myeloma; Myelodysplastic Syndromes 77. Recruiting Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H Conditions: Myelodysplastic Disorders; Leukemia; Multiple Myeloma; Plasma Cell Dyscrasia; Lymphoproliferative Disorders 78. Recruiting Safety and pharmacokinetics of orally administered gallium maltolate in various refractory malignancies. Conditions: Prostatic Neoplasms; Multiple Myeloma; Bladder Neoplasms; Lymphoma 79. Recruiting Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Condition: cancer 80. Recruiting Oxaliplatin in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult diffuse small cleaved cell lymphoma; ... 81. Recruiting Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Conditions: leukemia; lymphoma 82. Recruiting Bryostatin 1 Plus Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma Conditions: lymphoma; leukemia 83. Recruiting Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia Conditions: lymphoma; leukemia 84. Recruiting Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia Conditions: Waldenstrom's macroglobulinemia; refractory plasma cell neoplasm 85. Recruiting Monoclonal Antibody Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma Condition: lymphoma 86. Recruiting Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers Conditions: leukemia; lymphoma 87. Recruiting Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult diffuse small cleaved cell lymphoma; ... 88. Recruiting Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Conditions: recurrent adult diffuse small noncleaved cell/Burkitt's lymphoma; recurrent adult T-cell leukemia/lymphoma; ... 89. Recruiting PS-341 in Treating Patients With Lymphoproliferative Disorders Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent grade III follicular large cell lymphoma; recurrent mantle cell lymphoma; ... 90. Recruiting Arsenic Trioxide in Treating Patients With Relapsed or Refractory Indolent Lymphoproliferative Disorders Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; refractory chronic lymphocytic leukemia; refractory hairy cell leukemia; ... 91. Recruiting Study of Systemic Amyloidosis Presentation and Prognosis Condition: Amyloidosis 92. Recruiting STI571 in Treating Patients With Advanced Cancer and Liver Dysfunction Conditions: leukemia; lymphoma; eye cancer 93. Recruiting Dexamethasone Plus Interferon alfa in Treating Patients With Primary Systemic Amyloidosis Condition: primary systemic amyloidosis 94. Recruiting FR901228 in Treating Patients With Hematologic Cancer Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; untreated adult acute myeloid leukemia; refractory chronic lymphocytic leukemia; ... 95. Recruiting PS-341 in Treating Patients With Waldenstrom's Macroglobulinemia Condition: Waldenstrom's macroglobulinemia 96. Recruiting Stem Cell Transplant Therapy with Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome Conditions: Mycosis Fungoides; Sezary Syndrome 97. Recruiting 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder Conditions: leukemia; lymphoma 98. Recruiting Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia Condition: Waldenstrom's macroglobulinemia 99. Recruiting Comparison of Fludarabine Plus Total-body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma ... Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult diffuse small cleaved cell lymphoma; ... 100. Recruiting Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Condition: Waldenstrom's macroglobulinemia 103 studies were found. Here are studies 101 to 103. 101. Recruiting Rituximab With or Without Interleukin-12 in Treating Patients With Non-Hodgkin's Lymphoma Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent mantle cell lymphoma; Waldenstrom's macroglobulinemia; ... 102. Recruiting Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma Conditions: stage I grade II follicular mixed cell lymphoma; contiguous stage II diffuse small lymphocytic/marginal zone lymphoma; ... 103. Recruiting Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Aplastic Anemia or Hematologic Cancer Conditions: leukemia; lymphoma; eye cancer http://clinicaltrials.gov/ct/gui/action/ChangeQuery;jsessionid=CA1D3A8E717C3ECA5E9F85F62EF90907 Search results for granuloma [ALL-FIELDS] are shown below. -------------------------------------------------------------------------------- 13 studies were found. 1. Recruiting Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Conditions: Purpura, Schoenlein-Henoch; Graft Versus Host Disease; Anemia, Hemolytic, Autoimmune; Rheumatoid Arthritis; Churg-Strauss Syndrome; ... 2. Recruiting Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Conditions: salivary gland cancer; lip and oral cavity cancer; head and neck cancer; oropharyngeal cancer 3. Recruiting Docetaxel in Treating Patients With Solid Tumors Conditions: lung cancer; lip and oral cavity cancer; head and neck cancer; bladder cancer; oropharyngeal cancer; breast cancer 4. Recruiting Chemotherapy in Treating Patients With Advanced Solid Tumors or Refractory Hematologic Cancers Conditions: lung cancer; gastric cancer; lip and oral cavity cancer; leukemia; renal cell cancer; head and neck cancer; colorectal cancer; ovarian sarcoma; ... 5. Recruiting Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Conditions: lung cancer; pancreatic cancer; gastric cancer; lip and oral cavity cancer; esophageal cancer; head and neck cancer; adult primary liver cancer; ... 6. Not yet recruiting Docetaxel and St. 's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Conditions: lung cancer; lip and oral cavity cancer; head and neck cancer; bladder cancer; prostate cancer; oropharyngeal cancer; breast cancer 7. Recruiting Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Conditions: lip and oral cavity cancer; head and neck cancer; oropharyngeal cancer 8. Recruiting Erlotinib and Irinotecan in Treating Patients With Advanced Solid Tumors Conditions: lung cancer; lip and oral cavity cancer; esophageal cancer; head and neck cancer; colorectal cancer; colon cancer; brain tumor; oropharyngeal cancer; ... 9. Recruiting Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Conditions: lung cancer; pancreatic cancer; lip and oral cavity cancer; esophageal cancer; head and neck cancer; colorectal cancer; ovarian epithelial cancer; ... 10. Recruiting Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Conditions: lip and oral cavity cancer; skin cancer; head and neck cancer; lymphoma; Kaposi's sarcoma; oropharyngeal cancer; breast cancer 11. Recruiting Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Condition: cancer 12. Recruiting UCN-01 and Irinotecan in Treating Patients With Metastatic or Unresectable Solid Tumors Conditions: lung cancer; pancreatic cancer; gastric cancer; lip and oral cavity cancer; endometrial cancer; esophageal cancer; head and neck cancer; ... 13. Recruiting Treatment of Pulmonary Sarcoidosis with Pentoxifylline Condition: Pulmonary Sarcoidosis http://clinicaltrials.gov/ct/gui/action/SearchAction;jsessionid=CA1D3A8E717C3ECA5E9F85F62EF90907?term=granuloma & submit=Search & granulomata.ID=term & granulomata.badWord=granulomatas & granulomatous.ID=term & granulomatous.badWord=granulomatas This study, having been completed is very interesting if you notice that much of this knowledge was known before most of us received implants. It will also make you feel like a bio\chemical warfare toxic dumping site ~kathi Search results for phosgene 1 study was found. 1. Completed Specialized Center of Research in Occupational and Immunologic Lung Disease Conditions: Lung Diseases, Obstructive; Asbestosis; Silicosis; Pneumoconiosis; Chronic Obstructive Pulmonary Disease REF: Butcher BT, RN, O'Neil CE, Glindmeyer HW, Diem JE, Dharmarajan V, Weill H, Salvaggio JE. Longitudinal study of workers employed in the manufacture of toluene-diisocyanate. Am Rev Respir Dis. 1977 Sep;116(3):411-21. Butcher BT, Salvaggio JE, O'Neil CE, Weill H, Garg O. Toluene diisocyanate pulmonary disease: immunopharmacologic and mecholyl challenge studies. J Allergy Clin Immunol. 1977 Mar;59(3):223-7. Butcher BT, RN, O'Neil CE, Glindmeyer HW, Diem JE, Dharmarajan V, Weill H, Salvaggio JE. Longitudinal study of workers employed in the manufacture of toluene-diisocyanate. Am Rev Respir Dis. 1977 Sep;116(3):411-21. Dharmarajan V. Analysis of toluene diisocyanate (TDI) and p, p1-diphenylmethane diisocyanate (MDI) in air. Am Ind Hyg Assoc J. 1977 Dec;38(12):725-6. No abstract available. RN, Rando RJ, Glindmeyer HW, TA, JM, O'Neil CE, Weill H. Abnormal lung function in polyurethane foam producers. Weak relationship to toluene diisocyanate exposures. Am Rev Respir Dis. 1992 Oct;146(4):871-7. Palmgren MS, deShazo RD, RM, Zimny ML, Shah SV. Mechanisms of neutrophil damage to human alveolar extracellular matrix: the role of serine and metalloproteases. J Allergy Clin Immunol. 1992 Apr;89(4):905-15. RN, Weill H, Ziskind M. Pulmonary function in sandblasters' silicosis. Bull Physiopathol Respir (). 1975 Jul-Aug;11(4):589-95. Samimi B, Neilson A, Weill H, Ziskind M. The efficiency of protective hoods used by sandblasters to reduce silica dust exposure. Am Ind Hyg Assoc J. 1975 Feb;36(2):140-8. Butcher BT, Salvaggio JE, Weill H, Ziskind MM. Toluene diisocyanate (TDI) pulmonary disease: immunologic and inhalation challenge studies. J Allergy Clin Immunol. 1976 Jul;58(1 PT 1):89-100. RN, -Warwick M, Ziskind M, Weill H. High prevalence of antinuclear antibodies in sandblasters' silicosis. Am Rev Respir Dis. 1976 Mar;113(3):393-5. Ziskind M, Weill H, AE, Samimi B, Neilson A, Waggenspack C. Silicosis in shipyard sandblasters. Environ Res. 1976 Apr;11(2):237-43. No abstract available. Weill H: Silicosis - Method of Hans Weill MD. In: Conn (Ed), Current Therapy, 146-147, 1976 Schuyler M, Ziskind M, Salvaggio J. Cell-mediated immunity in silicosis. Am Rev Respir Dis. 1977 Jul;116(1):147-51. -Warwick M, Cole P, Weill H, RN, Ziskind M: Chemical Fibrosis: The Model of Silica. Ann Rheum Dis, 36:47-50, 1977 Dharmarajan V, Weill H. Physical state of airborne p, p'-diphenylmethane diisocyanate (MDI) and its measurement. Am Ind Hyg Assoc J. 1978 Sep;39(9):737-44. Dharmarajan V, Weil H, Self CW. Environmental characterization of toluene diisocyanate (TDI) in a manufacturing plant. Am Ind Hyg Assoc J. 1978 May;39(5):414-8. No abstract available. Dharmarajan V, Weill H. Physical state of airborne p, p'-diphenylmethane diisocyanate (MDI) and its measurement. Am Ind Hyg Assoc J. 1978 Sep;39(9):737-44. Dharmarajan V: Occupational Exposures to Methylene Diphenyl Diisocyanate (MDI) Gaseous or Aerosol? J Environ Toxicol & Pathol, 1978 Diem JE, Glindmeyer HW, Weill H: A Sensitive Procedure for Detecting the Presence of an Acute Bronchoconstrictor Response in Occupational Populations. Am Rev Respir Dis, 4:229, 1978 Butcher BT. Inhalation challenge testing with toluene diisocyanate. J Allergy Clin Immunol. 1979 Dec;64(6 pt 2):655-7. No abstract available. Butcher BT, Karr RM, O'Neil CE, MR, Dharmarajan V, Salvaggio JE, Weill H. Inhalation challenge and pharmacologic studies of toluene diisocyanate (TDI)-sensitive workers. J Allergy Clin Immunol. 1979 Aug;64(2):146-52. Dharmarajan V, Rando RJ. A new method for the generation of standard atmospheres of organo isocyanates. Am Ind Hyg Assoc J. 1979 Oct;40(10):870-6. Schuyler MR, Ziskind MM, Salvaggio J. Function of lymphocytes and monocytes in silicosis. Chest. 1979 Mar;75(3):340-4. Butcher BT, Karr RM: Toluene Diisocyanate-Induced Asthma. In: Preger L (Ed), Induced Disease - Drug, Irradiation, Occupation. New York: Grune and Stratton, 317-327, 1979 Dharmarajan V, Rando RJ: A New Method for the Generation of Standard Atmospheres of Toluene Diisocyanate. In: Proceedings of the American Industrial Hygiene Conference, Chicago, 1979 Weill H, Butcher B, Diem JE, Dharmarajan V, Glindmeyer HW, RN, Carr J, O'Neil C, Salvaggio J: Respiratory and Immunologic Evaluation of Isocyanate Exposure in a New Manufacturing Plant. Final Report, NIOSH Contract No. 210-75-0006, 1979. Published as a NIOSH Technical Document, 1979 Butcher BT, O'Neil CE, MA, Salvaggio JE, Weill H. Development and loss of toluene diisocyanate reactivity: immunologic, pharmacologic, and provocative challenge studies. J Allergy Clin Immunol. 1982 Oct;70(4):231-5. Diem JE, RN, Hendrick DJ, Glindmeyer HW, Dharmarajan V, Butcher BT, Salvaggio JE, Weill H. Five-year longitudinal study of workers employed in a new toluene diisocyanate manufacturing plant. Am Rev Respir Dis. 1982 Sep;126(3):420-8. Hendrick DJ, Rando RJ, Lane DJ, MJ. Formaldehyde asthma: challenge exposure levels and fate after five years. J Occup Med. 1982 Nov;24(11):893-7. Hines WH, Banks DE: A Review of Silicosis. Practical Cardiology, 8:97-107, 1982 CE, deShazo R. Immunologic aspects of granulomatous and interstitial lung diseases. JAMA. 1982 Nov 26;248(20):2683-91. No abstract available. Robins J, Greaves IA, Eisen EA. Five-year longitudinal study of workers employed in a new toluene diisocyanate manufacturing plant. Am Rev Respir Dis. 1983 Aug;128(2):327-8. No abstract available. Doll NJ, Stankus RP, Barkman HW. Immunopathogenesis of asbestosis, silicosis, and coal workers' pneumoconiosis. Clin Chest Med. 1983 Jan;4(1):3-14. Review. Fabbri LM, Mapp CE, Hendrick DJ. Effect of cromolyn on carbachol-induced bronchoconstriction. Ann Allergy. 1983 Mar;50(3):195-8. Hendrick DJ: The Formaldehyde Problem - a Clinical Appraisal. Immunol and Allergy Practice, 5:97-108, 1983 Hendrick DJ: THe Formaldehyde Problem: a Clinical Appraisal (Corresp). Immunol and Allergy Practice, 5:290-291, 1983 Rando RJ, Abdel-Kader HM, Hammad YY. Isomeric composition of airborne TDI in the polyurethane foam industry. Am Ind Hyg Assoc J. 1984 Mar;45(3):199-203. Stankus R, Banks DE: Immunologic Alterations in Silicosis. In: Petty TL, Cherniak RM (Eds), Salvaggio JE, deShazo RD (Guest Eds), Seminars in Respiratory Medicine. New York: Thieme-Stratton Inc., 1984 Stankus RP, deShazo RD, Doll NJ, Salvaggio JE: Immunologic Markers of Disease Severity in Human Silicosis. Clin Res, 32:847, 1984 Stankus RP, Salvaggio JE: Interstitial Lung Disease. Interspecialty Focus, 3:1, 1984 Butcher BT: Isocyanate-Induced Respiratory Disease. Folia Allergologica et Immunologica Clinica, 32:29-34, 1985 Stankus RP: Bronchopulmonary Lavage in the Diagnosis of Pulmonary Immune Disease. In: McMann E (Ed), Principles and Techniques of Human Research and Therapeutics. Futura, 37-50, 1985 Stankus RP, Salvaggio JE: Immunodiagnostic Techniques in Human Lung Research: Bronchoalveolar Lavage. In: McMann E (Ed), Principles and Techniques of Human Research and Therapeutics. Futura, 37-50, 1985 Banks DE, Barkman HW Jr, Butcher BT, Hammad YY, Rando RJ, Glindmeyer HW 3rd, RN, Weill H. Absence of hyperresponsiveness to methacholine in a worker with methylene diphenyl diisocyanate (MDI)-induced asthma. Chest. 1986 Mar;89(3):389-93. Hendrick DJ, Fabbri LM, JM, Banks DE, Barkman HW Jr, Connolly MJ, RN, Weill H. Modification of the methacholine inhalation test and its epidemiologic use in polyurethane workers. Am Rev Respir Dis. 1986 Apr;133(4):600-4. RN, JM, Glindmeyer H, Weill H. Lung function after acute chlorine exposure. Am Rev Respir Dis. 1986 Dec;134(6):1190-5. Weissman DN, deShazo RD, Banks DE. Modulation of natural killer cell function by human alveolar macrophages. J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):571-7. RN, JM, Glindmeyer H, Weill H. Lung function after acute chlorine exposure. Am Rev Respir Dis. 1986 Dec;134(6):1190-5. Banks DE, Butcher BT, Salvaggio JE. Isocyanate-induced respiratory disease. Ann Allergy. 1986 Dec;57(6):389-96. Review. No abstract available. Rando RJ, Abdel-Kader H, J, Hammad YY. Toluene diisocyanate exposures in the flexible polyurethane foam industry. Am Ind Hyg Assoc J. 1987 Jun;48(6):580-5. Rando RJ, Duvoisin PF, Abdel-Kader H, Hammad YY. A sequential tape monitor for toluene diisocyanate. Am Ind Hyg Assoc J. 1987 Jun;48(6):574-9. Rando RJ, Abdel-Kader H, J, Hammad YY. Toluene diisocyanate exposures in the flexible polyurethane foam industry. Am Ind Hyg Assoc J. 1987 Jun;48(6):580-5. Rando RJ, Duvoisin PF, Abdel-Kader H, Hammad YY. A sequential tape monitor for toluene diisocyanate. Am Ind Hyg Assoc J. 1987 Jun;48(6):574-9. Sastre J, Banks DE, Ellis E, Barkman HW, Butcher BT, Hammad YY, Rando RJ, Glindmeyer HW: Isocyanate-Induced Asthma: Review of 62 Challenge Tests. Am Rev Respir Dis, 135:A235, (Supplement), 1987 Banks DE, Salvaggio J, Goetzel EJ: Eosinophilic Syndromes of the Lung. In: Murray FJ, Nadel JA (Eds), Textbook of Respiratory Medicine, Philadelphia: Saunders, 1988